Analysis of drug scale with anticholinergic activity
DOI:
https://doi.org/10.30968/rbfhss.2023.143.0937Abstract
Objective: To identify the anticholinergic drug scales and analyse the agreement regarding the drugs included. Methods: This is a descriptive study on scales of drugs with anticholinergic activity. The scales were identified through bibliographical research. The drugs presented in the scales and the systematic classification of the anticholinergic activity score were identified. The drugs included in the scales that were registered with the National Health Surveillance Agency - ANVISA were verified. The drugs included were recorded in an Excel spreadsheet and were classified according to level 3 of the systematic Anatomical Therapeutic Chemistry – ATC of the World Health Organization (WHO). Kappa Fleiss analysis was performed to assess the agreement between the scales in relation to the drugs present. The scales were compared according to the Kappa Cohen statistic. Results: 25 scales for measuring anticholinergic activity were identified. The most recent scale with the largest number of drugs is the Crideco Anticholinergic Activity Scale – CALS. The Anticholinergic Burden Classification – ABC has a smaller number of drugs. Regarding the scoring system, most scales use a score from 0 to 3. In the scales, 347 synthetic drugs and two plant extracts (belladonna and scopolia) were identified. The extracts were considered in this study as a natural product, considering the type of plant present in the extract. For purposes of totaling the numbers of drugs present in the scales, 349 were considered. The most frequent drugs were from subgroup N06A - antidepressants, N05B - anxiolytics and A02B - drugs for peptic ulcer and gastroesophageal reflux disease. The most prevalent pharmacological subgroups were: N06A - antidepressants, N05A - antipsychotics and R06A - antihistamines. Most of the drugs present in the scales had indirect anticholinergic activity. According to Kappa Cohen statistics, only 10 pairs of scales showed moderate agreement. Conclusion: There are 25 scales available for measuring anticholinergic activity. The agreement between the identified scales regarding the drugs included is regular. Considering the drugs included and the pairs of scales, weak and fair agreement prevailed.
Downloads
References
Ramos H, Moreno L, Pérez-Tur J, et al. CRIDECO Anticholinergic Load Scale: An Updated Anticholinergic Burden Scale. Comparison with the ACB Scale in Spanish Individuals with Subjective Memory Complaints. J Pers Med. 2022; 12(2):207. doi: 10.3390/jpm12020207.
Lavrador, AMAAP. Quantificação da carga anticolinérgica como preditor de resultados clínicos negativos no idoso–um contributo para a prática clínica [Tese de doutorado]. Universidade de Coimbra, Coimbra, 2022.
Nishtala PS, Salahudeen MS, Hilmer SN. Anticholinergics: theoretical and clinical overview. Expert Opin Drug Saf. 2016;15(6):753-68. doi: 10.1517/14740338.2016.1165664.
Soysal T, Akın S, Durmuş NŞ, et al. Comparison of Anticholinergic Burden Measured with Three Different Anticholinergic Risk Scales and Association with Cognitive and Physical Functions in Older Adults. Arch GerontolGeriatr. 2021; 96:104451.
Lisibach A, Benelli V, Ceppi MG, et al. Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur J ClinPharmacol. 2021; 77(2):147-162. doi: 10.1007/s00228-020-02994-x.
López-Álvarez J, Sevilla-Llewellyn-Jones J, Agüera-Ortiz L. Anticholinergic Drugs in Geriatric Psychopharmacology. Front Neurosci. 2019;13:1309. doi: 10.3389/fnins.2019.01309.
Nery RT, Reis AMM. Development of a Brazilian anticholinergic activity drug scale. Einstein (Sao Paulo). 2019;17(2):eAO4435. doi: 10.31744/einstein_journal/2019AO4435.
Lisibach A, Gallucci G, Beeler PE, et al. High anticholinergic burden at admission associated with in-hospital mortality in older patients: A comparison of 19 different anticholinergic burden scales. Basic Clin PharmacolToxicol. 2022; 130(2):288-300. doi: 10.1111/bcpt.13692.
Lima, MS; Reis, AM. Identificação da atividade anticolinérgica dos medicamentos da Relação Nacional de Medicamentos Essenciais. Ver BrasFarmHospServ Saúde. 2020; 11(2):1-8.
Klamer TT, Wauters M, Azermai M, et al. A Novel Scale Linking Potency and Dosage to Estimate Anticholinergic Exposure in Older Adults: the Muscarinic Acetylcholinergic Receptor ANTagonist Exposure Scale. Basic ClinPharmacolToxicol. 2017;120(6):582-590. doi: 10.1111/bcpt.12699.
Whalley LJ, Sharma S, Fox HC, et al. Anticholinergic drugs in late life: adverse effects on cognition but not on progress to dementia. J Alzheimers Dis. 2012;30(2):253-261.doi:10.3233/JAD-2012-110935.
Aizenberg D, Sigler M, Weizman A, Barak Y. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. IntPsychogeriatr. 2002;14(3):307-310. doi:10.1017/s1041610202008505.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-74.
Ancelin ML, Artero S, Portet F, et al. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455-459.
Summers WK. A clinical method of estimating risk of drug induced delirium. Life Sci. 1978; 22(17):1511-6.
Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008; 56(7):1333-41.
Ehrt U, Broich K, Larsen JP, et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J NeurolNeurosurg Psychiatry. 2010; 81(2):160-5. doi: 10.1136/jnnp.2009.186239.
Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004; 161(1):116-24. doi: 10.1176/appi.ajp.161.1.116.
Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J ClinPharmacol. 2013; 69(7):1485-96. doi: 10.1007/s00228-013-1499-3.
Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015; 15:31. doi: 10.1186/s12877-015-0029-9.
Xu D, Anderson HD, Tao A, et al. Assessing and predicting drug-induced anticholinergic risks: an integrated computational approach. TherAdv Drug Saf. 2017; 8(11):361-370. doi: 10.1177/2042098617725267.
Lavrador M, Cabral AC, Veríssimo MT, et al. A Universal Pharmacological-Based List of Drugs with Anticholinergic Activity. Pharmaceutics. 2023 Jan 10;15(1):230. doi: 10.3390/pharmaceutics15010230.
Al Rihani SB, Deodhar M, Darakjian LI, et al. Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models. Drugs Aging. 2021;38(11):977-994. doi: 10.1007/s40266-021-00895-x.
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-694. doi: 10.1111/jgs.15767.
Lertxundi U, Domingo-Echaburu S, Hernandez R, et al. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics. 2013 Mar;13(1):17-24. doi: 10.1111/j.1479-8301.2012.00418.x.
Pont LG, Nielen JT, McLachlan AJ, et al. Measuring anticholinergic drug exposure in older community-dwelling Australian men: a comparison of four different measures. Br J Clin Pharmacol. 2015 Nov;80(5):1169-75. doi: 10.1111/bcp.12670.
Naples JG, Marcum ZA, Perera S, et al. Concordance Between Anticholinergic Burden Scales. J Am Geriatr Soc. 2015 Oct;63(10):2120-4. doi: 10.1111/jgs.13647.
Javelot H, Meyer G, Becker G, et al. Les échellesanticholiner giques: usage enpsychiatrie et mise à jour de l’échelled’imprégnationanticholinergique [Anticholinergic scales: Use in psychiatry and update of the anticholinergic impregnation scale]. Encephale. 2022; 48(3):313-324.
Jun K, Hwang S, Ah YM, et al. Development of an Anticholinergic Burden Scale specific for Korean older adults. GeriatrGerontol Int. 2019; 19(7):628-634. doi: 10.1111/ggi.13680.
Carnahan RM, Lund BC, Perry PJ, et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J ClinPharmacol. 2006; 46(12):1481-6. doi: 10.1177/0091270006292126.
Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi: 10.1186/s12877-018-0929-6.
Hefner G, Shams M, Wenzel-Seifert K, et al. Rating the delirogenic potential of drugs for prediction of side effects in elderly psychiatric inpatients. JJ Pharma Pharmacovigilance. 2015; 1(1): 003, 2015.
Nguyen P, Pelletier L, Payot I, et al. Drug Delirium Scale (DDS): a tool to evaluate drugs as a risk factor for Delirium. International Journal of Innovative Research in Medical Science. 2016;1(6):232-7.
Bishara D, Harwood D, Sauer J, et al. Anticholinergic effect on cognition (AEC) of drugs commonly used in older people. Int J Geriatr Psychiatry. 2017; 32(6):650-656. doi:10.1002/gps.4507.
Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: a review and practical application. Ageing Health. 2008;4(3):311.
Kable A, Fullerton A, Fraser S, et al. Comparison of Potentially Inappropriate Medications for People with Dementia at Admission and Discharge during An Unplanned Admission to Hospital: Results from the SMS Dementia Study. Healthcare (Basel). 2019;7(1):8.
Sittironnarit G, Ames D, Bush AI, et al. Effects of anticholinergic drugs on cognitive function in older Australians: results from the AIBL study. Dement GeriatrCognDisord. 2011;31(3):173-8. doi: 10.1159/000325171.
Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161(8):1099-105. doi: 10.1001/archinte.161.8.1099.
Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008; 168(5):508-13. doi: 10.1001/archinternmed.2007.106.
Cancelli I, Gigli GL, Piani A, et al. Drugs with anticholinergic properties as a risk factor for cognitive impairment in elderly people: a population-based study. J ClinPsychopharmacol. 2008;28(6):654-9. doi: 10.1097/JCP.0b013e31818ce849.
Cao YJ, Mager DE, SimonsickEM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. ClinPharmacolTher. 2008;83(3):422-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
